Qiong Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qiong Wu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chao Sun
College of Animal Science and Technology Northwest A&F University Yangling China
3 shared publications - Yizhou Li
College of Animal Science and Technology, Northwest A&F University, Xianyang 712100, China
3 shared publications - Yongnian Liu
Department of Basic Medical Sciences, Key Laboratory for Application of High Altitude Medicine, Qinghai University, Xining, China
3 shared publications - Yuexia Liu
College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi 712100, China
3 shared publications - Zhuwen Sun
College of Animal Science and Technology, Northwest A&F University, Xianyang 712100, China
3 shared publications - Juntong Liang
College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi 712100, China
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (7) , 203
Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?
Despite advances in multimodal therapy, pancreatic ductal adenocarcinoma (PDAC) remains a highly fatal tumor. For surgically resectable and borderline-resectable PDAC (BR-PDAC), the optimal integration of neoadjuvant chemotherapy and radiotherapy has yet to be established. Recent randomized studies (e.g., ESPAC-5F, NORPACT-1, Alliance A021501, and PREOPANC) and updated guidelines [of the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and Japanese Society of Hepato‑Biliary‑Pancreatic Surgery (JASPAC)] now identify which patients are likely to benefit from treatment before surgery. For resectable PDAC, upfront surgery followed by adjuvant chemotherapy (typically modified FOLFIRINOX) remains the standard of care. However, new research (e.g., Prep-02/JSAP05) suggests that some high-risk patients may benefit from neoadjuvant therapy. For BR-PDAC, neoadjuvant multiagent chemotherapy (typically FOLFIRINOX) is widely accepted as the standard approach for increasing the likelihood of margin-negative resection and improving survival. Induction chemotherapy (with or without ablative radiotherapy) is commonly employed to downstage tumors in locally advanced PDAC. Debate continues as to the role of radiotherapy [either conventional chemoradiotherapy or stereotactic body radiotherapy (SBRT)]. PREOPANC reported a slight survival benefit for preoperative gemcitabine-based chemoradiotherapy in resectable PDAC and BR-PDAC, while Alliance A021501 reported no additional benefit from SBRT following FOLFIRINOX in BR-PDAC. Advanced imaging [multiphasic computed tomography/magnetic resonance imaging (CT/MRI) and positron emission tomography/computed tomography (PET/CT)] enhances the precision of staging and response evaluation. Molecular diagnostics, particularly germline/somatic BRCA and KRAS status and circulating tumor DNA (ctDNA) monitoring, are currently informing perioperative decisions and innovative therapeutics. As of 2025, personalized perioperative care guided by resectability status, tumor biology, and patient-specific characteristics has emerged as the key strategy for optimizing the selection of patients for neoadjuvant chemotherapy and/or radiotherapy. This review sought to synthesize the most recent evidence and guidelines on the treatment of resectable, BR, and locally advanced PDAC.
- 1 July 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (7) , 203
Open AccessPerioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?
Despite advances in multimodal therapy, pancreatic ductal adenocarcinoma (PDAC) remains a highly fatal tumor. For surgically resectable and borderline-resectable PDAC (BR-PDAC), the optimal integration of neoadjuvant chemotherapy and radiotherapy has yet to be established. Recent randomized studies (e.g., ESPAC-5F, NORPACT-1, Alliance A021501, and PREOPANC) and updated guidelines [of the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and Japanese Society of Hepato‑Biliary‑Pancreatic Surgery (JASPAC)] now identify which patients are likely to benefit from treatment before surgery. For resectable PDAC, upfront surgery followed by adjuvant chemotherapy (typically modified FOLFIRINOX) remains the standard of care. However, new research (e.g., Prep-02/JSAP05) suggests that some high-risk patients may benefit from neoadjuvant therapy. For BR-PDAC, neoadjuvant multiagent chemotherapy (typically FOLFIRINOX) is widely accepted as the standard approach for increasing the likelihood of margin-negative resection and improving survival. Induction chemotherapy (with or without ablative radiotherapy) is commonly employed to downstage tumors in locally advanced PDAC. Debate continues as to the role of radiotherapy [either conventional chemoradiotherapy or stereotactic body radiotherapy (SBRT)]. PREOPANC reported a slight survival benefit for preoperative gemcitabine-based chemoradiotherapy in resectable PDAC and BR-PDAC, while Alliance A021501 reported no additional benefit from SBRT following FOLFIRINOX in BR-PDAC. Advanced imaging [multiphasic computed tomography/magnetic resonance imaging (CT/MRI) and positron emission tomography/computed tomography (PET/CT)] enhances the precision of staging and response evaluation. Molecular diagnostics, particularly germline/somatic BRCA and KRAS status and circulating tumor DNA (ctDNA) monitoring, are currently informing perioperative decisions and innovative therapeutics. As of 2025, personalized perioperative care guided by resectability status, tumor biology, and patient-specific characteristics has emerged as the key strategy for optimizing the selection of patients for neoadjuvant chemotherapy and/or radiotherapy. This review sought to synthesize the most recent evidence and guidelines on the treatment of resectable, BR, and locally advanced PDAC.
- 15 February 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 106, 108608
Leptin: an entry point for the treatment of peripheral tissue fibrosis and related diseases
- 15 February 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 106, 108608
Leptin: an entry point for the treatment of peripheral tissue fibrosis and related diseases
- Open Access
- 16 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (22) , 12353
The Mechanism of Leptin on Inhibiting Fibrosis and Promoting Browning of White Fat by Reducing ITGA5 in Mice
Leptin is a small molecule protein secreted by adipocytes, which can promote white fat browning through activating the hypothalamic nervous system and inhibiting downstream signaling pathways. Moreover, white fat browning has been proven to alleviate fat tissue fibrosis. This study explores the mechanism of leptin in regulating adipose tissue fibrosis and white fat browning. After treating mice with leptin, we screened out the recombinant integrin alpha 5 (ITGA5) through proteomics sequencing, which may play a role in adipose tissue fibrosis. Through real-time quantitative PCR (qPCR), western blotting (WB), hematoxylin-eosin (HE) staining, Masson’s trichrome, immunofluorescence, immunohistochemistry, etc., the results showed that after leptin treated adipocytes, the expression of fibrosis-related genes and ITGA5 was significantly down-regulated in adipocytes. We constructed fibrosis model through transforming growth factor-β (TGF-β) and a high-fat diet (HFD), and treated with ITGA5 overexpression vector and interference fragments. The results indicated the expression of fibrosis-related genes were significantly down-regulated after interfering with ITGA5. After treating adipocytes with wortmannin, fibrosis-related gene expression was inhibited after overexpression of ITGA5. Moreover, after injecting mice with leptin, we also found that leptin significantly up-regulated the expression of adipose tissue browning-related genes. Overall, our research shows that leptin can inhibit the activation of phosphatidylinositol 3 kinase (PI3K)-protein kinase B (AKT) signaling pathway by reducing the expression of ITGA5, which could alleviate adipose tissue fibrosis, and further promote white fat browning. Our research provides a theoretical basis for further research on the effect of leptin in fibrosis-related adipose tissue metabolism.
- 16 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (22) , 12353
Open AccessThe Mechanism of Leptin on Inhibiting Fibrosis and Promoting Browning of White Fat by Reducing ITGA5 in Mice
Leptin is a small molecule protein secreted by adipocytes, which can promote white fat browning through activating the hypothalamic nervous system and inhibiting downstream signaling pathways. Moreover, white fat browning has been proven to alleviate fat tissue fibrosis. This study explores the mechanism of leptin in regulating adipose tissue fibrosis and white fat browning. After treating mice with leptin, we screened out the recombinant integrin alpha 5 (ITGA5) through proteomics sequencing, which may play a role in adipose tissue fibrosis. Through real-time quantitative PCR (qPCR), western blotting (WB), hematoxylin-eosin (HE) staining, Masson’s trichrome, immunofluorescence, immunohistochemistry, etc., the results showed that after leptin treated adipocytes, the expression of fibrosis-related genes and ITGA5 was significantly down-regulated in adipocytes. We constructed fibrosis model through transforming growth factor-β (TGF-β) and a high-fat diet (HFD), and treated with ITGA5 overexpression vector and interference fragments. The results indicated the expression of fibrosis-related genes were significantly down-regulated after interfering with ITGA5. After treating adipocytes with wortmannin, fibrosis-related gene expression was inhibited after overexpression of ITGA5. Moreover, after injecting mice with leptin, we also found that leptin significantly up-regulated the expression of adipose tissue browning-related genes. Overall, our research shows that leptin can inhibit the activation of phosphatidylinositol 3 kinase (PI3K)-protein kinase B (AKT) signaling pathway by reducing the expression of ITGA5, which could alleviate adipose tissue fibrosis, and further promote white fat browning. Our research provides a theoretical basis for further research on the effect of leptin in fibrosis-related adipose tissue metabolism.
- Open Access
- 16 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (18) , 9997
Collagen XV Promotes ER Stress-Induced Inflammation through Activating Integrin β1/FAK Signaling Pathway and M1 Macrophage Polarization in Adipose Tissue
Collagen XV (Col XV), a basement membrane (BM) component, is highly expressed in adipose tissue, and studies have found that Col XV is related to extracellular matrix (ECM) remodeling involving in adipose tissue fibrosis and inflammation. Furthermore, the ECM is essential for maintaining normal development and tissue function. In this study, we found that Col XV is related to the endoplasmic reticulum stress (ERS) and inflammation of adipose tissue. Moreover, we found that overexpression of Col XV in mice could cause macrophages to infiltrate white adipose tissue (iWAT). At the same time, the expression of the ERS sensor IRE1α (Inositol-Requiring Enzyme-1α) was significantly up-regulated, which intensified the inflammation of adipose tissue and the polarization of M1 macrophages after the overexpression of Col XV in mice. In addition, after overexpression of Col XV, the intracellular Ca2+ concentration was significantly increased. Using focal adhesion kinase (FAK) inhibitor PF573228, we found that PF-573228 inhibited the phosphorylation of FAK and reversed the upward trend of Col XV-induced protein expression levels of IRE1α, C/EBP-homologous protein (CHOP), and 78 kDa glucose-regulated protein (GRP78). After treatment with IRE1α inhibitor STF-083010, the results showed that the expression of adipocyte inflammation-related genes interleukin 6 (IL-6) and tumor necrosis factor α (TNFα) significantly were decreased. Our results demonstrate that Col XV induces ER-stress in adipocytes by activating the Integrinβ1/FAK pathway and disrupting the intracellular Ca2+ balance. At the same time, Col XV regulates the inflammation induced by ER stress in adipocytes by promoting IRE1α/XBP1 (X-Box binding protein 1) signaling. Our study provides new ideas for solving the problems of adipose tissue metabolism disorders caused by abnormal accumulation of ECM.
- 16 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (18) , 9997
Open AccessCollagen XV Promotes ER Stress-Induced Inflammation through Activating Integrin β1/FAK Signaling Pathway and M1 Macrophage Polarization in Adipose Tissue
Collagen XV (Col XV), a basement membrane (BM) component, is highly expressed in adipose tissue, and studies have found that Col XV is related to extracellular matrix (ECM) remodeling involving in adipose tissue fibrosis and inflammation. Furthermore, the ECM is essential for maintaining normal development and tissue function. In this study, we found that Col XV is related to the endoplasmic reticulum stress (ERS) and inflammation of adipose tissue. Moreover, we found that overexpression of Col XV in mice could cause macrophages to infiltrate white adipose tissue (iWAT). At the same time, the expression of the ERS sensor IRE1α (Inositol-Requiring Enzyme-1α) was significantly up-regulated, which intensified the inflammation of adipose tissue and the polarization of M1 macrophages after the overexpression of Col XV in mice. In addition, after overexpression of Col XV, the intracellular Ca2+ concentration was significantly increased. Using focal adhesion kinase (FAK) inhibitor PF573228, we found that PF-573228 inhibited the phosphorylation of FAK and reversed the upward trend of Col XV-induced protein expression levels of IRE1α, C/EBP-homologous protein (CHOP), and 78 kDa glucose-regulated protein (GRP78). After treatment with IRE1α inhibitor STF-083010, the results showed that the expression of adipocyte inflammation-related genes interleukin 6 (IL-6) and tumor necrosis factor α (TNFα) significantly were decreased. Our results demonstrate that Col XV induces ER-stress in adipocytes by activating the Integrinβ1/FAK pathway and disrupting the intracellular Ca2+ balance. At the same time, Col XV regulates the inflammation induced by ER stress in adipocytes by promoting IRE1α/XBP1 (X-Box binding protein 1) signaling. Our study provides new ideas for solving the problems of adipose tissue metabolism disorders caused by abnormal accumulation of ECM.
- 1 January 2020
- Vol. 13 (11) , 2860-2869
Neuroprotective effect of intermittent hypobaric hypoxia preconditioning on cerebral ischemia/reper fusion in rats
Background: Ischemic tolerance is an endogenous protective mechanism in organs or tissues undergoing one or more short-term sublethal ischemias. Intermittent hypobaric hypoxia preconditioning (IHHP) can induce tolerance and thus protect brain tissues from cerebral ischemic injury (CIR). The current study evaluated the neuroprotective effect of IHHP. Methods: The established xenograft model was divided into the ischemia/reper fusion (I/R), IHHP, IHHP+I/R, and sham groups. Transmission electron microscopy was used to observe alterations in neuron ultrastructure. Neuron damage was detected using Nissl staining. Western blot and qRT-PCR were used to evaluate the relative expression of genes and proteins related to apoptosis. Immunohistochemistry was used to determine the expression of proteins involved in the processes of neuroprotection and repair. Results: Our results indicated that the damage to the neurons, organelles, and axons was significantly less following ischemia/reper fusion and intermittent hypobaric hypoxia reconditioning treatment than that in the ischemia/reper fusion group. Compared to the ischemia/reper fusion group, significant downregulation of pro-apoptotic gene/protein expressions along with upregulation of anti-apoptotic and nerve regeneration gene/protein expressions in the IHHP+I/R group were observed. Conclusion: IHHP can significantly reduce ischemia/reper fusion injury in rat brain nerves and promote nerve repair.
- 1 January 2020
- Vol. 13 (11) , 2860-2869
Neuroprotective effect of intermittent hypobaric hypoxia preconditioning on cerebral ischemia/reper fusion in rats
Background: Ischemic tolerance is an endogenous protective mechanism in organs or tissues undergoing one or more short-term sublethal ischemias. Intermittent hypobaric hypoxia preconditioning (IHHP) can induce tolerance and thus protect brain tissues from cerebral ischemic injury (CIR). The current study evaluated the neuroprotective effect of IHHP. Methods: The established xenograft model was divided into the ischemia/reper fusion (I/R), IHHP, IHHP+I/R, and sham groups. Transmission electron microscopy was used to observe alterations in neuron ultrastructure. Neuron damage was detected using Nissl staining. Western blot and qRT-PCR were used to evaluate the relative expression of genes and proteins related to apoptosis. Immunohistochemistry was used to determine the expression of proteins involved in the processes of neuroprotection and repair. Results: Our results indicated that the damage to the neurons, organelles, and axons was significantly less following ischemia/reper fusion and intermittent hypobaric hypoxia reconditioning treatment than that in the ischemia/reper fusion group. Compared to the ischemia/reper fusion group, significant downregulation of pro-apoptotic gene/protein expressions along with upregulation of anti-apoptotic and nerve regeneration gene/protein expressions in the IHHP+I/R group were observed. Conclusion: IHHP can significantly reduce ischemia/reper fusion injury in rat brain nerves and promote nerve repair.